Drug Type Biosimilar, Monoclonal antibody |
Synonyms Complarate, Tocilizumab Biosimilar (Generium ZAO), 托珠单抗生物类似药(Generium ZAO) + [2] |
Target |
Action antagonists |
Mechanism IL-6RA antagonists(Interleukin-6 receptor alpha subunit antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D02596 | Tocilizumab Biosimilar (Generium) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Rheumatoid Arthritis | Phase 3 | Russia | 01 Dec 2022 |






